A
Antonio L. Dans
Researcher at University of the Philippines
Publications - 131
Citations - 19863
Antonio L. Dans is an academic researcher from University of the Philippines. The author has contributed to research in topics: Population & Internal medicine. The author has an hindex of 46, co-authored 114 publications receiving 15661 citations. Previous affiliations of Antonio L. Dans include University of the Philippines Manila & Philippine General Hospital.
Papers
More filters
Journal ArticleDOI
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study
Martin O'Donnell,Martin O'Donnell,Denis Xavier,Lisheng Liu,Hongye Zhang,Siu Lim Chin,Purnima Rao-Melacini,Sumathy Rangarajan,Shofiqul Islam,Prem Pais,Matthew J. McQueen,Charles Mondo,Albertino Damasceno,Patricio Lopez-Jaramillo,Graeme J. Hankey,Antonio L. Dans,Khalid Yusoff,Thomas Truelsen,Hans-Christoph Diener,Ralph L. Sacco,Danuta Ryglewicz,Anna Członkowska,Christian Weimar,Xingyu Wang,Salim Yusuf +24 more
TL;DR: The findings suggest that ten risk factors are associated with 90% of the risk of stroke, and targeted interventions that reduce blood pressure and smoking, and promote physical activity and a healthy diet, could substantially reduce the burden of stroke.
Journal ArticleDOI
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly,John W. Eikelboom,Campbell D. Joyner,Hans-Christoph Diener,Robert G. Hart,Sergey P. Golitsyn,Greg C. Flaker,Alvaro Avezum,Stefan H. Hohnloser,Rafael Diaz,Mario Talajic,Jun Zhu,Prem Pais,Andrzej Budaj,Alexander Parkhomenko,Petr Jansky,Patrick J. Commerford,Ru San Tan,Kui-Hian Sim,Basil S. Lewis,Walter Van Mieghem,Jae Hyung Kim,Fernando Lanas-Zanetti,Antonio Gonzalez-Hermosillo,Antonio L. Dans,Muhammad Munawar,John H. Lawrence,Gayle Lewis,Rizwan Afzal,Salim Yusuf +29 more
TL;DR: In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing therisk of major bleeding or intracranial hemorrhage.
Journal ArticleDOI
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
John W. Eikelboom,Stuart J. Connolly,Jackie Bosch,Gilles R. Dagenais,Robert G. Hart,Olga Shestakovska,Rafael Diaz,Marco Alings,Eva Lonn,Sonia S. Anand,Petr Widimsky,Masatsugu Hori,Alvaro Avezum,Leopoldo S. Piegas,Kelley R. Branch,Jeffrey L. Probstfield,Deepak L. Bhatt,Jun Zhu,Yan Liang,Aldo P. Maggioni,Patricio Lopez-Jaramillo,Martin O'Donnell,Ajay K. Kakkar,Keith A.A. Fox,Alexander Parkhomenko,Georg Ertl,Stefan Störk,Matyas Keltai,Lars Rydén,Nana Pogosova,Antonio L. Dans,Fernando Lanas,Patrick J. Commerford,Christian Torp-Pedersen,Tomek J. Guzik,Peter Verhamme,Dragos Vinereanu,Jae-Hyung Kim,Andrew Tonkin,Basil S. Lewis,Camilo Felix,Khalid Yusoff,P. Gabriel Steg,Kaj Metsärinne,Nancy Cook Bruns,Frank Misselwitz,Edmond Chen,Darryl P. Leong,Salim Yusuf +48 more
TL;DR: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assign to aspirin alone.
Journal ArticleDOI
Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study
Martin O'Donnell,Martin O'Donnell,Siu Lim Chin,Sumathy Rangarajan,Denis Xavier,Lisheng Liu,Hongye Zhang,Purnima Rao-Melacini,Xiaohe Zhang,Prem Pais,Steven Agapay,Patricio Lopez-Jaramillo,Albertino Damasceno,Peter Langhorne,Matthew J. McQueen,Annika Rosengren,Mahshid Dehghan,Graeme J. Hankey,Antonio L. Dans,Ahmed Elsayed,Alvaro Avezum,Charles Mondo,Hans-Christoph Diener,Danuta Ryglewicz,Anna Członkowska,Nana Pogosova,Christian Weimar,Romaina Iqbal,Rafael Diaz,Khalid Yusoff,Khalid Yusoff,Afzalhussein Yusufali,Aytekin Oguz,Xingyu Wang,Ernesto Peñaherrera,Fernando Lanas,Okechukwu S Ogah,Adesola Ogunniyi,Helle K. Iversen,Germán Málaga,Zvonko Rumboldt,Shahram Oveisgharan,Fawaz Al Hussain,Daliwonga Magazi,Yongchai Nilanont,John Ferguson,Guillaume Paré,Salim Yusuf +47 more
TL;DR: The importance of potentially modifiable risk factors for stroke in different regions of the world, and in key populations and primary pathological subtypes of stroke, was quantified.
Journal ArticleDOI
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial
Lars Wallentin,Salim Yusuf,Michael D. Ezekowitz,Marco Alings,Marcus Flather,Maria Grazia Franzosi,Prem Pais,Antonio L. Dans,John W. Eikelboom,Jonas Oldgren,Janice Pogue,Paul A. Reilly,Sean Yang,Stuart J. Connolly +13 more
TL;DR: Results show that local standards of care affect the benefits of use of new treatment alternatives, and both doses at reducing intracranial bleeding versus warfarin were consistent irrespective of centres' quality of INR control.